{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T15:58:34Z","timestamp":1772899114777,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009769","name":"Mats Klebergs Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006350","name":"Stiftelsen Clas Groschinskys Minnesfond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006350","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010769","name":"Petrus och Augusta Hedlunds Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006285","name":"Magnus Bergvalls Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006285","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Virological Methods"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jviromet.2025.115258","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T18:09:30Z","timestamp":1757095770000},"page":"115258","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Evaluation of two IgG-scFv bispecific antibodies for neutralizing Omicron variants of SARS-CoV-2"],"prefix":"10.1016","volume":"339","author":[{"given":"Diana","family":"Hinojosa-Trujillo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Freddy","family":"Dehesa-Canseco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Garc\u00eda-Vega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ver\u00f3nica","family":"Mata-Haro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Sol\u00eds-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00f3nica","family":"Res\u00e9ndiz-Sandoval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanglei","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harold","family":"Marcotte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jviromet.2025.115258_bib1","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.ade0958","article-title":"Human neutralizing antibodies to cold linear epitopes and subdomain 1 of the SARS-CoV-2 spike glycoprotein","volume":"8","author":"Bianchini","year":"2023","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.jviromet.2025.115258_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112014","article-title":"Bivalent intra-spike binding provides durability against emergent omicron lineages: results from a global consortium","volume":"42","author":"Callaway","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.jviromet.2025.115258_bib3","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.1038\/s41467-022-33030-4","article-title":"IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concern","volume":"13","author":"Chang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jviromet.2025.115258_bib4","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41590-022-01147-9","article-title":"Bispecific antiviral neutralizing antibodies are twice as nice","volume":"23","author":"Crowe","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jviromet.2025.115258_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2023.106562","article-title":"19n01, a broadly neutralizing antibody against omicron BA.1, BA.2, BA.4\/5, and other SARS-CoV-2 variants of concern","volume":"26","author":"Garc\u00eda-Vega","year":"2023","journal-title":"IScience"},{"key":"10.1016\/j.jviromet.2025.115258_bib6","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/s41586-021-03461-y","article-title":"Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice","volume":"593","author":"De Gasparo","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jviromet.2025.115258_bib7","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1080\/14712598.2022.2040987","article-title":"The evolution of bispecific antibodies","volume":"22","author":"Gera","year":"2022","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.jviromet.2025.115258_bib8","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41392-023-01447-y","article-title":"Neutralization of omicron BA.1, BA.5.1.6, BQ.1.3 and XBB1.1 induced by heterologous vaccination Ad5-nCoV and mRNA-1273","volume":"8","author":"Hern\u00e1ndez","year":"2023","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.jviromet.2025.115258_bib9","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/s41590-023-01449-6","article-title":"Infection with wild-type SARS-CoV-2 elicits broadly neutralizing and protective antibodies against omicron subvariants","volume":"24","author":"Ju","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jviromet.2025.115258_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105576","article-title":"Novel bispecific human antibody platform specifically targeting a fully open spike conformation potently neutralizes multiple SARS-CoV-2 variants","volume":"212","author":"Kim","year":"2023","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jviromet.2025.115258_bib11","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s41590-022-01138-w","article-title":"An engineered bispecific human monoclonal antibody against SARS-CoV-2","volume":"23","author":"Li","year":"2022","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jviromet.2025.115258_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellin.2024.100150","article-title":"Function and mechanism of bispecific antibodies targeting SARS-CoV-2","volume":"3","author":"Li","year":"2024","journal-title":"Cell Insight"},{"key":"10.1016\/j.jviromet.2025.115258_bib13","first-page":"15","article-title":"Selection of bispecific antibodies with optimal developability using FcRn-pH-HPLC as an optimized FcRn affinity chromatography method","author":"M\u00fcller","year":"2023","journal-title":"MAbs"},{"key":"10.1016\/j.jviromet.2025.115258_bib14","doi-asserted-by":"crossref","first-page":"13540","DOI":"10.1073\/pnas.1304985110","article-title":"Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1","volume":"110","author":"Pace","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jviromet.2025.115258_bib15","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201181","article-title":"Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses","volume":"217","author":"Schmidt","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jviromet.2025.115258_bib16","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/QAI.0000000000000218","article-title":"Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36","volume":"66","author":"Sun","year":"2014","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.jviromet.2025.115258_bib17","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1016\/j.cell.2021.03.029","article-title":"Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein","volume":"184","author":"Suryadevara","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jviromet.2025.115258_bib18","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41421-022-00463-6","article-title":"Combating the SARS-CoV-2 omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies","volume":"8","author":"Wang","year":"2022","journal-title":"Cell Discov."},{"key":"10.1016\/j.jviromet.2025.115258_bib19","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1038\/s41589-022-01140-1","article-title":"Converting non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitors","volume":"18","author":"Weidenbacher","year":"2022","journal-title":"Nat. Chem. Biol."}],"container-title":["Journal of Virological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016609342500151X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016609342500151X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T20:54:51Z","timestamp":1772830491000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016609342500151X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":19,"alternative-id":["S016609342500151X"],"URL":"https:\/\/doi.org\/10.1016\/j.jviromet.2025.115258","relation":{},"ISSN":["0166-0934"],"issn-type":[{"value":"0166-0934","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of two IgG-scFv bispecific antibodies for neutralizing Omicron variants of SARS-CoV-2","name":"articletitle","label":"Article Title"},{"value":"Journal of Virological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jviromet.2025.115258","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115258"}}